Anticonvulsants

Medical Marijuana, Inc. Subsidiary HempMeds® Announces Partnership with Northshore Pharmacy to Sell Real Scientific Hemp Oil™ in Bermuda

Retrieved on: 
Wednesday, May 9, 2018
Cannabis, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, Hemp, Medical Marijuana, Inc., Pharmacy

Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced its subsidiary HempMeds has partnered with Northshore Pharmacy to sell its Real Scientific Hemp Oil (RSHO) CBD oil as a non-prescription product in Bermuda.

Key Points: 
  • Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced its subsidiary HempMeds has partnered with Northshore Pharmacy to sell its Real Scientific Hemp Oil (RSHO) CBD oil as a non-prescription product in Bermuda.
  • "We feel very fortunate to partner with this prestigious pharmacy to help expand CBD access throughout Bermuda."
  • Northshore Pharmacy is owned by the husband and wife team of Jonathan and Jennie Lightbourne.
  • "Our pharmacy is pleased to offer HempMeds' CBD hemp oil products to our customers," said Northshore Pharmacy Co-Owner and Managing Pharmacist, Jennie Lightbourne.

Amneal Launches Generic for Sabril®: Vigabatrin for Oral Solution, USP

Retrieved on: 
Wednesday, May 2, 2018
Chemistry, Organic chemistry, Amines, Anticonvulsants, Vigabatrin, Food and Drug Administration, Health

BRIDGEWATER, N.J., May 2, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has launched vigabatrin for oral solution USP, a generic equivalent for Sabril.

Key Points: 
  • BRIDGEWATER, N.J., May 2, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has launched vigabatrin for oral solution USP, a generic equivalent for Sabril.
  • Annual U.S. sales of vigabatrin for oral solution (brand and generic) were $318 million, according to March 2018 IQVIA market data.
  • The Amneal generic product received FDA approval under a Risk Evaluation and Mitigation Strategy (REMS) known as the Vigabatrin REMS program.
  • Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.